secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2024-04-02T23:59:59+00:00
Accession:  0001683168-24-002050
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals reports 2023 net loss of $10.8M; cash at $8.5M with PH-762 trial progress
--------------------------------------------------------------------------------

- Net loss $10.8M ($5.20/share) vs $11.5M ($10.10/share) in 2022; R&D expenses down 10% to $6.3M.
- Cash at Dec 31, 2023: $8.5M, down from $11.8M at end of 2022.
- PH-762 Phase 1B: two patients completed treatment with no adverse events; four clinical sites under contract.
- Headcount reduced 36% and Marlborough lease not renewed; moved to 321 sq ft lab in Worcester.
- AgonOx study delayed; facility renovation expected to reopen May 2024; third patient infused in Nov 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824002050/0001683168-24-002050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316824002050/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-002050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer